Paine Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PNS012 MIFTS: 60	Paine Syndrome Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Paine Syndrome

MalaCards integrated aliases for Paine Syndrome:

Name: Paine Syndrome ⁵⁸ ⁵⁴ ⁷⁴

Pain Disorder ¹² ⁵⁶ ¹⁵ ⁷⁴

Pain ⁶ ⁴⁴ ¹⁷

Microcephaly with Spastic Diplegia ⁵⁸ ⁵⁴

Pain Syndrome ¹⁵

Characteristics:

OMIM:

⁵⁸

Inheritance:
x-linked

HPO:

³³

paine syndrome:
Inheritance x-linked inheritance

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Mental diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

General symptoms and signs

Pain, not elsewhere classified

Pain, unspecified

External Ids:

Disease Ontology ¹² DOID:0060164

OMIM ⁵⁸ 311400

ICD10 ³⁴ R52 R52.9

MedGen ⁴³ C1412041

SNOMED-CT via HPO ⁷⁰ 192992007 263934009 267581004 more

EFO ¹⁷ EFO_0003843

UMLS ⁷⁴ C0391976 C1412041

Sources

Summaries for Paine Syndrome

MedlinePlus : ⁴⁴ Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Paine Syndrome, also known as pain disorder, is related to familial episodic pain syndrome and complex regional pain syndrome. An important gene associated with Paine Syndrome is PTPRQ (Protein Tyrosine Phosphatase Receptor Type Q), and among its related pathways/superpathways are Development Endothelin-1/EDNRA signaling and Neuropathic Pain-Signaling in Dorsal Horn Neurons. The drugs Acetaminophen and Dinoprostone have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and brain, and related phenotypes are microcephaly and generalized myoclonic seizures

Disease Ontology : ¹² A somatoform disorder that involves chronic pain in one or more areas, and is thought to be caused by psychological stress.

Description from OMIM: 311400

Sources

Related Diseases for Paine Syndrome

Diseases in the Paine Syndrome family:

Central Pain Syndrome

Pain - Chronic

Diseases related to Paine Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2800)

#	Related Disease	Score	Top Affiliating Genes
1	familial episodic pain syndrome	34.1	SCN11A TRPA1
2	complex regional pain syndrome	33.9	IL1B SCN9A TAC1
3	indifference to pain, congenital, autosomal recessive	33.9	SCN10A SCN11A SCN9A
4	interstitial cystitis	33.2	NGF TAC1 TRPV1
5	causalgia	32.6	NGF SCN10A SCN11A TAC1
6	esophagitis, eosinophilic, 1	31.8	ATP12A ATP4A
7	neuroschistosomiasis	31.7	NGF TAC1
8	prurigo nodularis	31.7	NGF TAC1
9	hernia, hiatus	31.6	ATP12A ATP4A
10	lateral medullary syndrome	31.6	ATP12A ATP4A
11	peripheral nervous system disease	31.5	NGF SCN9A TAC1 TRPV1
12	superior mesenteric artery syndrome	31.4	ATP12A ATP4A
13	lymphocytic colitis	31.4	ATP12A ATP4A
14	paroxysmal extreme pain disorder	31.3	SCN10A SCN11A SCN9A TRPV1
15	cystitis	31.3	NGF TAC1 TRPV1
16	autonomic nervous system disease	31.3	NGF TAC1
17	esophageal candidiasis	31.2	ATP12A ATP4A
18	laryngitis	31.0	ATP12A ATP4A IL1B
19	toxic megacolon	30.9	ATP12A ATP4A
20	rumination disorder	30.9	ATP12A ATP4A
21	lesion of sciatic nerve	30.7	NGF SCN10A TRPV1
22	polyposis, skin pigmentation, alopecia, and fingernail changes	30.7	ATP12A ATP4A CABIN1
23	jejunoileitis	30.2	NGF IL1B ATP4A ATP12A
24	trigeminal neuralgia	29.8	SCN10A SCN9A TRPV1
25	dyskinesia of esophagus	29.8	ATP12A ATP4A
26	chronic intestinal vascular insufficiency	29.7	ATP12A ATP4A
27	esophageal disease	29.7	ATP12A ATP4A TRPV1
28	duodenitis	29.7	ATP12A ATP4A
29	stomach disease	29.7	TRPV1 SCN10A IL1B ATP4A ATP12A
30	bile reflux	29.7	ATP12A ATP4A
31	erythromelalgia	29.6	SCN10A SCN9A
32	sciatic neuropathy	29.6	NGF SCN10A TRPV1
33	erythermalgia, primary	29.6	SCN10A SCN11A SCN9A
34	active peptic ulcer disease	29.6	ATP12A ATP4A
35	mononeuropathy	29.5	TAC1 TRPV1
36	diabetic neuropathy	29.5	NGF SCN9A TRPV1
37	burning mouth syndrome	29.4	TRPV1 TAC1 SCN9A NGF
38	corneal ulcer	29.4	IL1B NGF
39	migraine with or without aura 1	29.3	TAC1 TRPA1 TRPV1
40	pneumatosis cystoides intestinalis	29.3	ATP12A ATP4A
41	neuroma	29.2	NGF SCN10A TRPV1
42	laryngeal tuberculosis	29.2	ATP12A ATP4A
43	eosinophilic gastritis	29.2	ATP12A ATP4A
44	peptic ulcer perforation	29.0	ATP12A ATP4A
45	peptic esophagitis	29.0	ATP12A ATP4A IL1B
46	clostridium difficile colitis	29.0	ATP12A ATP4A IL1B
47	gastrointestinal system disease	28.9	ATP12A ATP4A IL1B TRPV1
48	ischemic neuropathy	28.8	ATP12A ATP4A NGF CABIN1
49	somatoform disorder	28.1	CABIN1 IL1B NGF SCN9A TAC1 TRPA1
50	insensitivity to pain, congenital, with anhidrosis	12.5

Graphical network of the top 20 diseases related to Paine Syndrome:

Sources

Symptoms & Phenotypes for Paine Syndrome

Human phenotypes related to Paine Syndrome:

³³

#	Description	HPO Source Accession
1	microcephaly ³³	HP:0000252
2	generalized myoclonic seizures ³³	HP:0002123
3	spastic diplegia ³³	HP:0001264
4	olivopontocerebellar hypoplasia ³³	HP:0006955

Symptoms via clinical synopsis from OMIM:

⁵⁸

Head:
microcephaly
hypoplasia of cerebellum, inferior olives and pons

Lab:
variable elevated spinal fluid amino acids

Neuro:
spastic diplegia
myoclonic seizures
absent abdominal reflexes

Clinical features from OMIM:

311400

MGI Mouse Phenotypes related to Paine Syndrome:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	9.81	INPP5D NGF PTPRQ SCN10A SCN11A SCN9A
2	integument	MP:0010771	9.61	IL1B INPP5D NGF SCN10A SCN11A SCN9A
3	taste/olfaction	MP:0005394	8.8	SCN9A TRPA1 TRPV1

Sources

Drugs & Therapeutics for Paine Syndrome

Drugs for Paine Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 535)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Acetaminophen

Approved

Phase 4,Phase 3,Not Applicable,Early Phase 1

103-90-2

1983

Dinoprostone

Approved

Phase 4

363-24-6

5280360

Histamine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Early Phase 1

51-45-6

774

Fexofenadine

Approved, Investigational

Phase 4

83799-24-0

3348

Gabapentin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Not Applicable

60142-96-3

3446

Pregabalin

Approved, Illicit, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

148553-50-8

5486971

Naltrexone

Approved, Investigational, Vet_approved

Phase 4,Not Applicable

16590-41-3

5360515

Ethanol

Approved

Phase 4,Phase 3,Not Applicable

64-17-5

702

Benzocaine

Approved, Investigational

Phase 4,Phase 1,Phase 2,Not Applicable

1994-09-7, 94-09-7

2337

Norepinephrine

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

51-41-2

439260

Levomilnacipran

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

96847-54-0

tannic acid

Approved

Phase 4,Phase 1,Phase 2,Not Applicable

1401-55-4

Milnacipran

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

92623-85-3

65833

Etoricoxib

Approved, Investigational

Phase 4,Phase 2

202409-33-4

123619

Cyclobenzaprine

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

303-53-7

2895

Amitriptyline

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

50-48-6

2160

Lidocaine

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

137-58-6

3676

Ropivacaine

Approved

Phase 4,Phase 3,Not Applicable

84057-95-4

175805 71273

Bupivacaine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

38396-39-3, 2180-92-9

2474

Triamcinolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable

124-94-7

31307

Acetylcholine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

51-84-3

187

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

50-02-2

5743

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

1177-87-3

Dopamine

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

62-31-7, 51-61-6

681

Tramadol

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

27203-92-5

33741

Perphenazine

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

58-39-9

4748

Hyaluronic acid

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

9004-61-9

53477741

Glycerol

Approved, Investigational

Phase 4,Phase 2

56-81-5

753

Cycloserine

Approved

Phase 4

68-41-7

6234 401

Colchicine

Approved

Phase 4

64-86-8

2833 6167

Dexmedetomidine

Approved, Vet_approved

Phase 4,Not Applicable

113775-47-6

5311068 68602

Dexlansoprazole

Approved, Investigational

Phase 4

138530-94-6, 103577-45-3

9578005

Lansoprazole

Approved, Investigational

Phase 4

103577-45-3

3883

Ketamine

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1

6740-88-1

3821

Diclofenac

Approved, Vet_approved

Phase 4,Phase 3,Not Applicable

15307-86-5

3033

Oxytocin

Approved, Vet_approved

Phase 4

50-56-6

53477758 439302

Remifentanil

Approved

Phase 4,Not Applicable

132875-61-7

60815

Saw palmetto

Approved, Experimental, Investigational

Phase 4

Trazodone

Approved, Investigational

Phase 4,Phase 2

19794-93-5

5533

Modafinil

Approved, Investigational

Phase 4

68693-11-8

4236

Fluoxetine

Approved, Vet_approved

Phase 4,Phase 3,Phase 2

54910-89-3

3386

Salmon Calcitonin

Approved, Investigational

Phase 4

47931-85-1

16129616

Granisetron

Approved, Investigational

Phase 4

109889-09-0

3510

Paroxetine

Approved, Investigational

Phase 4,Phase 1,Phase 2

61869-08-7

43815

Eszopiclone

Approved, Investigational

Phase 4

138729-47-2

969472

Betamethasone

Approved, Vet_approved

Phase 4,Phase 3,Not Applicable

378-44-9

9782

Metoprolol

Approved, Investigational

Phase 4,Not Applicable

37350-58-6, 51384-51-1

4171

Petrolatum

Approved, Investigational

Phase 4,Not Applicable

8009-03-8

Sodium Citrate

Approved, Investigational

Phase 4,Phase 3

68-04-2

Oxycodone

Approved, Illicit, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

76-42-6

5284603

Interventional clinical trials:

(show top 50) (show all 1430)

#	Name	Status	NCT ID	Phase	Drugs
1	Close Kinect Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome	Unknown status	NCT02241148	Phase 4	Acetaminophen 500mg
2	The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain	Unknown status	NCT01417923	Phase 4	vitamin D
3	Pregabalin for the Treatment of Uremic Pruritus	Unknown status	NCT01852318	Phase 4	pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
4	Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism?	Unknown status	NCT02806440	Phase 4	Low dose naltrexone;Placebo
5	Study of Fibromyalgia Treated With Milnacipran	Unknown status	NCT01125423	Phase 4	Milnacipran
6	Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia	Unknown status	NCT00755521	Phase 4	etoricoxib
7	Cyclobenzaprine Extended Release (ER) for Fibromyalgia	Unknown status	NCT01041495	Phase 4	cyclobenzaprine ER (AMRIX);placebo
8	Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain	Completed	NCT02385266	Phase 4	D-Cycloserine;Placebo (for D-cycloserine)
9	Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy.	Completed	NCT01250184	Phase 4	Lidocaine injection
10	EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes	Completed	NCT00272532	Phase 4	Thiocolchicoside
11	Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study	Completed	NCT02639039	Phase 4	Cortisone Injection
12	Effects of Dexmedetomidine Used in Continuous Thoracic Paravertebral Blocks	Completed	NCT02619513	Phase 4	Dexmedetomidine;Ropivacaine
13	Lansoprazole Versus Mosapride for Functional Dyspepsia	Completed	NCT00663897	Phase 4	lansoprazole;mosapride
14	Prophylactic Administration of Vitamin C in Wrist Fractures	Completed	NCT00296868	Phase 4	ascorbic acid (vitamin C) versus placebo
15	Pregabalin and Post-thoracotomy Pain	Completed	NCT00663962	Phase 4	Pregabalin;Placebo
16	Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain	Completed	NCT01067456	Phase 4
17	Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome	Completed	NCT03291197	Phase 4	Suprascapular and median nerve blocks
18	Restore Claims Characterization Study	Completed	NCT00200122	Phase 4
19	Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome	Completed	NCT00241215	Phase 4	Botulinum toxin serotype A
20	Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain	Completed	NCT03586154	Phase 4	ketamine and bupivacaine injection
21	A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions	Completed	NCT00904202	Phase 4	Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
22	Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood	Completed	NCT01495806	Phase 4	Glucomannan;placebo
23	Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain	Completed	NCT03241602	Phase 4	Intraperitoneal lidocaine
24	High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System	Completed	NCT02265848	Phase 4
25	Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy	Completed	NCT00800527	Phase 4	Gabapentin;Diclofenac
26	The Efficacy and Safety of Qizhiweitong Granule on Patients With Functional Dyspepsia in a Multi-center Clinical Study	Completed	NCT02460601	Phase 4	Qizhiweitong granule
27	Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain	Completed	NCT02024724	Phase 4	Bupivacaine;Triamcinolone;Dexamethasone
28	Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis	Completed	NCT00919802	Phase 4	Oxytocin
29	Bupivacaine Versus Lidocaine Local Anesthesia	Completed	NCT01751347	Phase 4	Bupivacaine;Lidocaine
30	Imaging Pain Relief in Osteoarthritis	Completed	NCT02208778	Phase 4	Duloxetine;Remifentanil;Placebo (for Remifentanil);Placebo (for Duloxetine)
31	Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis	Completed	NCT01195116	Phase 4	Dexmedetomidine;Normal Saline
32	Treatment of Chronic Bacterial Prostatitis	Completed	NCT02130713	Phase 4	Third generation fluoroquinolone
33	Discomfort and Psychosocial Difficulties in Fibromyalgia	Completed	NCT02078791	Phase 4	Botox infiltration
34	Strengthening Exercises for Fibromyalgia	Completed	NCT02063750	Phase 4
35	Heart Rate Variability in Fibromyalgia - Effects of Strengthening Exercises	Completed	NCT02004405	Phase 4
36	Quetiapine Compared With Placebo in the Management of Fibromyalgia	Completed	NCT01458964	Phase 4	Quetiapine
37	Effect of Milnacipran on Pain in Fibromyalgia	Completed	NCT01288807	Phase 4	Milnacipram
38	Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia	Completed	NCT01226667	Phase 4	Pregabalin
39	A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia	Completed	NCT01173055	Phase 4	milnacipran;Placebo
40	Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia	Completed	NCT01077375	Phase 4	Placebo;Milnacipran
41	Drug and Talk Therapy for Fibromyalgia	Completed	NCT01038323	Phase 4	Educational with milnacipran
42	Pregabalin In Adolescent Patients With Fibromyalgia	Completed	NCT01020526	Phase 4	pregabalin
43	Adolescent Fibromyalgia Study	Completed	NCT01020474	Phase 4	placebo;pregabalin (Lyrica)
44	Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia	Completed	NCT01014585	Phase 4	Placebo;Milnacipran
45	Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study	Completed	NCT00983320	Phase 4	quetiapine;placebo
46	A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia	Completed	NCT00965601	Phase 4
47	A Study for Adult Patients With Fibromyalgia	Completed	NCT00965081	Phase 4	Duloxetine;Placebo
48	Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia	Completed	NCT00791739	Phase 4	trazodone, pregabalin
49	An Efficacy Study of Combination of Tramadol and Acetaminophen Tablets in the Treatment of Participants With Fibromyalgia Pain	Completed	NCT00766675	Phase 4	Tramadol hydrochloride;Acetaminophen
50	Comparative Efficacy and Tolerability of Quetiapine XR and Amitriptyline in the Treatment of Fibromyalgia	Completed	NCT00766350	Phase 4	amitriptyline;quetiapine

Search NIH Clinical Center for Paine Syndrome

Sources

Genetic Tests for Paine Syndrome

Sources

Anatomical Context for Paine Syndrome

MalaCards organs/tissues related to Paine Syndrome:

⁴²

Prostate, Bone, Brain, Spinal Cord, Kidney, Thyroid, Endothelial

Sources

Publications for Paine Syndrome

Articles related to Paine Syndrome:

(show top 50) (show all 152)

#	Title	Authors	Year
1	Development and preliminary evaluation of a new screening instrument for atypical odontalgia and persistent dentoalveolar pain disorder. ( 30229950 )	Durham J...Nixdorf DR	2019
2	Reduced empathic pain processing in patients with somatoform pain disorder: Evidence from behavioral and neurophysiological measures. ( 30878486 )	Peng W...Yan D	2019
3	The role of coping with negative emotions in cognitive behavioral therapy for persistent somatoform pain disorder: is it more important than pain catastrophizing? ( 31102312 )	Yoshino A...Yamawaki S	2019
4	Persistent Dentoalveolar Pain Disorder: A Comprehensive Review. ( 29174443 )	Malacarne A...Maloney GE	2018
5	Comparison of pain, disorder, back performance, and psychological factors in patients with low back pain and radicular pain. ( 29410582 )	Kim S...Lee SM	2018
6	Bee Stings and Chronic Pain Disorder. ( 29545983 )	Steffen P...Noll-Hussong M	2018
7	Processing of Emotional Faces in Patients with Chronic Pain Disorder: An Eye-Tracking Study. ( 29556205 )	Giel KE...Junne F	2018
8	Cortical Thickness Alterations in Chronic Pain Disorder: An Exploratory MRI Study. ( 29787468 )	Magon S...Noll-Hussong M	2018
9	The Effectiveness of High-frequency Repetitive Transcranial Magnetic Stimulation in Persistent Somatoform Pain Disorder: A Case Series. ( 30083490 )	Singh SM...Avasthi A	2018
10	Granulocyte-macrophage colony-stimulating factor receptor expression in clinical pain disorder tissues and role in neuronal sensitization. ( 30534627 )	Donatien P...Anand P	2018
11	Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: An observational study. ( 28272220 )	Zhang M...Yan S	2017
12	The Fear-Avoidance Components Scale (FACS): Responsiveness to Functional Restoration Treatment in a Chronic Musculoskeletal Pain Disorder (CMPD) Population. ( 28328697 )	Neblett R...Gatchel RJ	2017
13	Altered resting-state intra- and inter- network functional connectivity in patients with persistent somatoform pain disorder. ( 28453543 )	Zhao Z...Luo Y	2017
14	Decreased prefrontal brain activation during verbal fluency task in patients with somatoform pain disorder: An exploratory multi-channel near-infrared spectroscopy study. ( 28499896 )	Ren X...Liu P	2017
15	Use of the Central Sensitization Inventory (CSI) as a treatment outcome measure for patients with chronic spinal pain disorder in a functional restoration program. ( 28619687 )	Neblett R...Gatchel RJ	2017
16	Somatoform Pain Disorder Presenting as "Atypical Facial Pain:" A Rare Presentation in a 13-year-old. ( 28852247 )	Shah R...Chauhan N	2017
17	Insecure attachment style and cumulative traumatic life events in patients with somatoform pain disorder: A cross-sectional study. ( 29167050 )	Nacak Y...Erim Y	2017
18	Treatment for Persistent Somatoform Pain Disorder via Electroacupuncture and a Low Dosage of Fluoxetine Hydrochloride. ( 30881254 )	Bai Y...Wu DH	2017
19	Advanced Genetic Testing Comes to the Pain Clinic to Make a Diagnosis of Paroxysmal Extreme Pain Disorder. ( 27525141 )	Cannon A...Riegert-Johnson DL	2016
20	Psychophysiological decoupling in alexithymic pain disorder patients. ( 26804974 )	Kleiman A...Conrad R	2016
21	Altered Spontaneous Activity in Patients with Persistent Somatoform Pain Disorder Revealed by Regional Homogeneity. ( 26977802 )	Huang T...Luo Y	2016
22	Low Level Laser Therapy Versus Pharmacotherapy in Improving Myofascial Pain Disorder Syndrome. ( 27330698 )	Khalighi HR...Moradi Abbasabadi F	2016
23	Altered Neural Correlates of Emotion Associated Pain Processing in Persistent Somatoform Pain Disorder: An fMRI Study. ( 27641732 )	Luo Y...Fan X	2016
24	Parental Protectiveness Mediates the Association between Parent-Perceived Child Self-Efficacy and Health Outcomes in Pediatric Functional Abdominal Pain Disorder. ( 27657151 )	DuPen MM...Levy RL	2016
25	Bilateral congenital corneal anesthesia in a patient with SCN9A mutation, confirmed primary erythromelalgia, and paroxysmal extreme pain disorder. ( 26486037 )	Kim DT...Ospina LH	2015
26	Short-lasting unilateral neuralgiform headache attacks with ispilateral facial flushing is a new variant of paroxysmal extreme pain disorder. ( 25903274 )	Imai N...Matsumoto N	2015
27	p.L1612P, a novel voltage-gated sodium channel Nav1.7 mutation inducing a cold sensitive paroxysmal extreme pain disorder. ( 25285947 )	Suter MR...Wider C	2015
28	What are the treatment options for paroxysmal extreme pain disorder? ( 26059255 )	Suter MR	2015
29	Prevalence of restless legs syndrome in somatoform pain disorder and its effect on quality of life. ( 25883472 )	Chatterjee SS...Chakraborty K	2015
30	Hypnotherapy of a pain disorder: a clinical case study. ( 25719524 )	Artimon HM	2015
31	Effectiveness of group cognitive behavioral therapy for somatoform pain disorder patients in Japan: A preliminary non-case-control study. ( 26129835 )	Yoshino A...Yamawaki S	2015
32	Amplified Brain Processing of Dentoalveolar Pressure Stimulus in Persistent Dentoalveolar Pain Disorder Patients. ( 26485382 )	Moana-Filho EJ...Nixdorf DR	2015
33	Effects of Kamishoyosan, a Traditional Japanese Kampo Medicine, on Pain Conditions in Patients with Intractable Persistent Dentoalveolar Pain Disorder. ( 26495024 )	Arai YC...Ushida T	2015
34	Psychogenic Pain Disorder--Differential Diagnosis and Treatment. ( 26529858 )	Chhabria A	2015
35	Self-management is key to fibromyalgia treatment. Treating this common chronic pain disorder has baffled patients and physicians for years. ( 25029737 )		2014
36	A comparison of schemas, schema modes and childhood traumas in obsessive-compulsive disorder, chronic pain disorder and eating disorders. ( 23689753 )	Voderholzer U...Zeeck A	2014
37	Painful micturition in a small child: an unusual clinical picture of paroxysmal extreme pain disorder. ( 24817410 )	Megli? A...Bertok S	2014
38	An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder. ( 23893323 )	Meijer IA...Rossignol E	2014
39	Effectiveness of a multimodal treatment program for somatoform pain disorder. ( 24305036 )	Pieh C...Lahmann C	2014
40	Facial affect perception and mentalizing abilities in female patients with persistent somatoform pain disorder. ( 24395204 )	Sch?nenberg M...Hautzinger M	2014
41	Factors influencing quality of life in Chinese patients with persistent somatoform pain disorder. ( 24428222 )	Luo YL...Zhang MY	2014
42	Distinctive spontaneous regional neural activity in patients with somatoform pain disorder: a preliminary resting-state fMRI study. ( 24439113 )	Yoshino A...Yamawaki S	2014
43	Healthcare pathway and biopsychosocial impact of persistent dentoalveolar pain disorder: a qualitative study. ( 24697333 )	Durham J...Nixdorf DR	2014
44	Pain as a late emotional reaction. Clinical research evaluating the psychosocial expression of pain disorder in preoperative and postoperative period. ( 25341289 )	Zavadovschi I	2014
45	Effectiveness of low-dose milnacipran for a patient suffering from pain disorder with delusional disorder (somatic type) in the orofacial region. ( 23909967 )	Ukai K...Ozaki N	2013
46	Paroxysmal extreme pain disorder. ( 23599527 )	Beck J...Noden J	2013
47	Functional network connectivity of pain-related resting state networks in somatoform pain disorder: an exploratory fMRI study. ( 22894821 )	Otti A...Noll-Hussong M	2013
48	Alexithymic and somatisation scores in patients with temporomandibular pain disorder correlate with deficits in facial emotion recognition. ( 23137311 )	Haas J...Busch V	2013
49	Neural correlates of deficits in pain-related affective meaning construction in patients with chronic pain disorder. ( 23362496 )	Noll-Hussong M...Guendel H	2013
50	Frequency shifts in the anterior default mode network and the salience network in chronic pain disorder. ( 23497482 )	Otti A...Noll-Hussong M	2013

Sources

Genes for Paine Syndrome

Genes related to Paine Syndrome (1 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	PTPRQ	Protein Tyrosine Phosphatase Receptor Type Q	Protein Coding	400	Pathogenic ⁶
2	SCN9A	Sodium Voltage-Gated Channel Alpha Subunit 9	Protein Coding	18.5	DISEASES inferred ¹⁵
3	NGF	Nerve Growth Factor	Protein Coding	16.63	DISEASES inferred ¹⁵
4	SCN11A	Sodium Voltage-Gated Channel Alpha Subunit 11	Protein Coding	16.56	DISEASES inferred ¹⁵
5	MSD	Microcephaly With Spastic Diplegia (Paine Syndrome)	Genetic Locus	16.55	GeneCards inferred via : Publications Gene name (show sections)
6	CABIN1	Calcineurin Binding Protein 1	Protein Coding	16.51	DISEASES inferred ¹⁵
7	TAC1	Tachykinin Precursor 1	Protein Coding	16.22	DISEASES inferred ¹⁵
8	TRPA1	Transient Receptor Potential Cation Channel Subfamily A Member 1	Protein Coding	16.16	DISEASES inferred ¹⁵
9	TRPV1	Transient Receptor Potential Cation Channel Subfamily V Member 1	Protein Coding	16	DISEASES inferred ¹⁵
10	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	15.52	DISEASES inferred ¹⁵
11	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	15.51	DISEASES inferred ¹⁵
12	SCN10A	Sodium Voltage-Gated Channel Alpha Subunit 10	Protein Coding	15.39	DISEASES inferred ¹⁵
13	IL1B	Interleukin 1 Beta	Protein Coding	15.21	DISEASES inferred ¹⁵
14	INPP5D	Inositol Polyphosphate-5-Phosphatase D	Protein Coding	15.14	DISEASES inferred ¹⁵
15	AOAH	Acyloxyacyl Hydrolase	Protein Coding	15.03	DISEASES inferred ¹⁵

Sources

Variations for Paine Syndrome

ClinVar genetic disease variations for Paine Syndrome:

⁶ (show all 16)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	KIF1B	NM_015074.3(KIF1B): c.2473G> A (p.Glu825Lys)	single nucleotide variant	Uncertain significance	rs763122049	GRCh37	Chromosome 1, 10384889: 10384889
2	KIF1B	NM_015074.3(KIF1B): c.2473G> A (p.Glu825Lys)	single nucleotide variant	Uncertain significance	rs763122049	GRCh38	Chromosome 1, 10324831: 10324831
3	SELENON	NM_020451.2(SELENON): c.482G> A (p.Arg161Gln)	single nucleotide variant	Uncertain significance	rs765749301	GRCh38	Chromosome 1, 25805220: 25805220
4	SELENON	NM_020451.2(SELENON): c.482G> A (p.Arg161Gln)	single nucleotide variant	Uncertain significance	rs765749301	GRCh37	Chromosome 1, 26131711: 26131711
5	OAT	NM_000274.3(OAT): c.875A> G (p.Lys292Arg)	single nucleotide variant	Likely pathogenic	rs1057518927	GRCh38	Chromosome 10, 124402952: 124402952
6	OAT	NM_000274.3(OAT): c.875A> G (p.Lys292Arg)	single nucleotide variant	Likely pathogenic	rs1057518927	GRCh37	Chromosome 10, 126091521: 126091521
7	SCN4A	NM_000334.4(SCN4A): c.1333G> T (p.Val445Leu)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs121908552	GRCh37	Chromosome 17, 62041947: 62041947
8	SCN4A	NM_000334.4(SCN4A): c.1333G> T (p.Val445Leu)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs121908552	GRCh38	Chromosome 17, 63964587: 63964587
9	GJB1	NM_001097642.2(GJB1): c.109G> T (p.Val37Leu)	single nucleotide variant	Likely pathogenic	rs1057518946	GRCh37	Chromosome X, 70443666: 70443666
10	GJB1	NM_001097642.2(GJB1): c.109G> T (p.Val37Leu)	single nucleotide variant	Likely pathogenic	rs1057518946	GRCh38	Chromosome X, 71223816: 71223816
11	COL5A1	NM_000093.4(COL5A1): c.608G> T (p.Gly203Val)	single nucleotide variant	Likely pathogenic	rs1554781700	GRCh37	Chromosome 9, 137593133: 137593133
12	COL5A1	NM_000093.4(COL5A1): c.608G> T (p.Gly203Val)	single nucleotide variant	Likely pathogenic	rs1554781700	GRCh38	Chromosome 9, 134701287: 134701287
13	PTPRQ	NM_001145026.1(PTPRQ): c.6475C> T (p.Arg2159Ter)	single nucleotide variant	Pathogenic	rs1445287184	GRCh37	Chromosome 12, 81064144: 81064144
14	PTPRQ	NM_001145026.1(PTPRQ): c.6475C> T (p.Arg2159Ter)	single nucleotide variant	Pathogenic	rs1445287184	GRCh38	Chromosome 12, 80670365: 80670365
15	MAP2K2	NM_030662.3(MAP2K2): c.514A> G (p.Lys172Glu)	single nucleotide variant	Uncertain significance	rs1413580671	GRCh37	Chromosome 19, 4102388: 4102388
16	MAP2K2	NM_030662.3(MAP2K2): c.514A> G (p.Lys172Glu)	single nucleotide variant	Uncertain significance	rs1413580671	GRCh38	Chromosome 19, 4102390: 4102390

Sources

Expression for Paine Syndrome

Search GEO for disease gene expression data for Paine Syndrome.

Sources

Pathways for Paine Syndrome

Pathways related to Paine Syndrome according to GeneCards Suite gene sharing:

(show all 11)

#	Super pathways	Score	Top Affiliating Genes
1	Development Endothelin-1/EDNRA signaling ²³ Show member pathways Cytoskeleton remodeling FAK signaling ²³ Development Endothelin-1/EDNRA transactivation of EGFR ²³ GnRH signaling pathway ³⁸ Inflammatory mediator regulation of TRP channels ³⁸	12.32	IL1B NGF TRPA1 TRPV1
2	Neuropathic Pain-Signaling in Dorsal Horn Neurons ⁶⁵ Show member pathways Aldosterone Signaling in Epithelial Cells ⁶⁵ Cholera Infection ⁶⁵	12.3	SCN10A SCN11A SCN9A TAC1
3	Neuroscience ⁴	12.16	NGF SCN10A SCN11A SCN9A
4	Cardiac conduction ⁶⁷ Show member pathways Classical Kir channels ⁶⁷ Ion homeostasis ⁶⁷ Ion transport by P-type ATPases ⁶⁷ Muscle contraction ⁶⁷ Phase 1 - inactivation of fast Na+ channels ⁶⁷ Phase 3 - rapid repolarisation ⁶⁷ Phase 4 - resting membrane potential ⁶⁷ Physiological factors ⁶⁷ Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK) ⁶⁷ Tandem pore domain halothane-inhibited K+ channel (THIK) ⁶⁷ Tandem pore domain potassium channels ⁶⁷ TWIK related potassium channel (TREK) ⁶⁷ TWIK-related alkaline pH activated K+ channel (TALK) ⁶⁷ TWIK-related spinal cord K+ channel (TRESK) ⁶⁷ TWIK-releated acid-sensitive K+ channel (TASK) ⁶⁷	12.08	ATP12A ATP4A SCN10A SCN11A SCN9A
5	Ion channel transport ⁶⁷ Show member pathways Stimuli-sensing channels ⁶⁷	12.05	ATP12A ATP4A TRPA1 TRPV1
6	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	11.87	IL1B NGF TAC1
7	L1CAM interactions ⁶⁷ Show member pathways CHL1 interactions ⁶⁷ Neurofascin interactions ⁶⁷ NrCAM interactions ⁶⁷	11.64	SCN10A SCN11A SCN9A
8	Phase 0 - rapid depolarisation ⁶⁷ Show member pathways Phase 2 - plateau phase ⁶⁷	11.21	SCN10A SCN11A SCN9A
9	Trk receptor signaling mediated by PI3K and PLC-gamma ¹	11	NGF TRPV1
10	TRP channels ⁶⁷	10.85	TRPA1 TRPV1
11	Interaction between L1 and Ankyrins ⁶⁷	10.28	SCN10A SCN11A SCN9A

Sources

GO Terms for Paine Syndrome

Cellular components related to Paine Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	axon	GO:0030424	9.35	NGF SCN10A SCN11A SCN9A TAC1
2	stereocilium bundle	GO:0032421	9.16	PTPRQ TRPA1
3	voltage-gated sodium channel complex	GO:0001518	8.8	SCN10A SCN11A SCN9A

Biological processes related to Paine Syndrome according to GeneCards Suite gene sharing:

(show all 22)

#	Name	GO ID	Score	Top Affiliating Genes
1	transmembrane transport	GO:0055085	9.89	SCN10A SCN11A SCN9A TRPA1 TRPV1
2	inflammatory response	GO:0006954	9.88	IL1B SCN9A TAC1 TRPV1
3	ion transmembrane transport	GO:0034220	9.81	SCN10A SCN9A TRPA1 TRPV1
4	regulation of ion transmembrane transport	GO:0034765	9.76	SCN10A SCN11A SCN9A
5	ion transport	GO:0006811	9.7	ATP12A ATP4A SCN10A SCN11A SCN9A TRPA1
6	sodium ion transmembrane transport	GO:0035725	9.65	SCN10A SCN11A SCN9A
7	ATP hydrolysis coupled proton transport	GO:0015991	9.6	ATP12A ATP4A
8	positive regulation of cytosolic calcium ion concentration	GO:0007204	9.59	TAC1 TRPV1
9	cellular sodium ion homeostasis	GO:0006883	9.57	ATP12A ATP4A
10	establishment or maintenance of transmembrane electrochemical gradient	GO:0010248	9.56	ATP12A ATP4A
11	cellular potassium ion homeostasis	GO:0030007	9.55	ATP12A ATP4A
12	sodium ion export across plasma membrane	GO:0036376	9.54	ATP12A ATP4A
13	neuronal action potential	GO:0019228	9.54	SCN10A SCN11A SCN9A
14	behavioral response to pain	GO:0048266	9.52	SCN9A TRPV1
15	response to pain	GO:0048265	9.5	TAC1 TRPA1 TRPV1
16	detection of chemical stimulus involved in sensory perception of pain	GO:0050968	9.46	TRPA1 TRPV1
17	fever generation	GO:0001660	9.43	IL1B TRPV1
18	membrane depolarization during action potential	GO:0086010	9.43	SCN10A SCN11A SCN9A
19	thermoception	GO:0050955	9.4	TRPA1 TRPV1
20	response to morphine	GO:0043278	9.3	TAC1
21	sodium ion transport	GO:0006814	9.13	SCN10A SCN11A SCN9A
22	sensory perception of pain	GO:0019233	9.02	SCN10A SCN9A TAC1 TRPA1 TRPV1

Molecular functions related to Paine Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	voltage-gated ion channel activity	GO:0005244	9.58	SCN10A SCN11A SCN9A
2	ion channel activity	GO:0005216	9.56	SCN10A SCN11A SCN9A TRPV1
3	calcium-release channel activity	GO:0015278	9.37	TRPA1 TRPV1
4	sodium:potassium-exchanging ATPase activity	GO:0005391	9.32	ATP12A ATP4A
5	potassium:proton exchanging ATPase activity	GO:0008900	9.16	ATP12A ATP4A
6	sodium channel activity	GO:0005272	9.13	SCN10A SCN11A SCN9A
7	voltage-gated sodium channel activity	GO:0005248	8.8	SCN10A SCN11A SCN9A

Sources

Sources for Paine Syndrome

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia